-
Metabolon Expands Microbiome Panel to Strengthen Industry Leadership in Functional Microbiome Research
Enhanced panel screens for more than 800 microbiome-associated metabolites, giving researchers a broader view of microbial activity linked to human health, nutrition, disease, and treatment response MORRISVILLE, N.C., July 15, 2026 /PRNewswire/ — Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, today announced an expansion of…
-
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners July 12, 2026 11:18 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data…
-
No easy answers: European research consortia take on major challenges
COPENHAGEN, Denmark, July 10, 2026 (GLOBE NEWSWIRE) — Nine new Challenge Programme grants from the Novo Nordisk Foundation will support ambitious research across fungal diseases, cardiometabolic disease, soil health and non-equilibrium biological systems. With a European expansion, the 2026 awards unite strong research groups and diverse expertise across Europe in the pursuit of novel knowledge…
-
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
July 07, 2026 09:12 ET | Source: Alamar Biosciences, Inc. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program…
-
Jelly Force Male Enhancement Gummies Release Latest Formula for Men: JellyForce Unique Ingredient Profile Report
Pinellas Park, FL, July 02, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the Food and Drug Administration. JellyForce is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use, especially if currently taking prescription medications. JellyForce is a gummy dietary supplement formulated for men,…
-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already approved and marketed in the United States as CREXONT®, providing established regulatory and commercial experience as the therapy advances toward European approval More than…
-
Zydus Hospital, Ahmedabad sets a new dimension in Alzheimer testing
A simple blood test can now detect AD early, boosting quality of life AHMEDABAD, India, June 19, 2026 /PRNewswire/ — As people grow older, changes occur in all parts of the body, including the brain. Forgetfulness can be a normal part of aging. Alzheimer’s disease (AD) is the most common type of dementia and can be…
-
JellyFil Publishes Updated 2026 Product Information for Its Premium Gummy Dietary Supplement, Including Full Ingredient List, Pricing, Refund Policy, and Customer Service Details
Largo, FL, June 20, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the U.S. Food and Drug Administration. JellyFil is not intended to diagnose, treat, cure, or prevent any disease. Consumers should consult a qualified healthcare professional before using any dietary supplement, particularly if currently taking prescription medications or managing existing health…
-
BreathEaseX Publishes Updated 2026 Product Information for Its Oral Spray Dietary Supplement, Including Full Ingredient List, Pricing, Refund Policy, and Customer Service Details
AURORA, CO, June 19, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the U.S. Food and Drug Administration. BreathEaseX is not intended to diagnose, treat, cure, or prevent any disease. Consumers should consult a qualified healthcare professional before using any dietary supplement, particularly if currently taking prescription medications or managing existing health…
-
SMT Celebrates 20 Years of the Cocoon Occluder Journey, Transforming Lives in Congenital and Structural Heart Defects
Mumbai, Maharashtra, India Congenital Heart Disease (CHD) is one of the most common birth defects, affecting approximately 1% of live births globally and accounting for more than 4.18 million cases in children under five1. Despite advances in medical care, CHD continues to be a leading cause of infant and child mortality, highlighting the need for…
-
Scottish football unites to tackle most common cancer in young men
Scottish football is uniting this weekend to tackle the most common cancer affecting young men, as clubs across the country back a national awareness campaign encouraging men to check themselves and catch the disease early. “Tackling Testicular Cancer”, led by Cahonas Scotland in partnership with PFA Scotland, is using the reach of the game to…
-
Fangzhou Showcases AI-Powered Chronic Disease Management Solution With Tencent Health at Tencent Cloud Conference
BEIJING, June 05, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, attended the 2026 Tencent Cloud AI Industry Applications Summit in Beijing, where it showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health. The conference, themed “Agent…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
